MetaCap

BlossomHill Therapeutics Inc. (BLSM)

NASDAQ: BLSMHealth CareBiotechnology: Pharmaceutical PreparationsUSD

14.51+0.10 (+0.69%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BLSM stock chart

Technical analysis

Key statistics

All statistics
Market cap
$461.20M
EPS (TTM)
-$10.38
52-week range
11.02 – 27.99
Day range
13.90 – 15.63
Volume / Avg
270.74K / 193.15K
Beta
—

52-week range

$11.02$27.99

BLSM stock today

On Nov 20, BLSM ended the session at $14.51, adding $0.10 (0.69%), versus the S&P 500's 3.70% decline. At this level, BLSM sits in the middle of its 52-week range of $11.02 to $27.99: 48.2% below the high, set on Sep 21, 2026 and 31.7% above the low. BlossomHill Therapeutics has posted a net loss over the last twelve months (EPS of -$10.38), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About BlossomHill Therapeutics

Company profile

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Jingrong Jean Cui Ph.D.
Headquarters
San Diego, CA
Employees
69
IPO year
2026

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$35.40+143.97%

  • Strong buy 1
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $30.00High $40.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-1.29 vs $-0.93
Surprise
-38.71%

BLSM news

All BLSM news

BlossomHill Therapeutics peers

Health Care sector
BLSM peer companies
CompanyPrice% ChgMarket capCompare
NGNENeurogene Inc.22.15-3.40%$458.53Mvs BLSM
GYREGyre Therapeutics Inc.4.21-6.86%$460.79Mvs BLSM
ASMBAssembly Biosciences Inc.22.19-1.38%$454.39Mvs BLSM
STTKShattuck Labs Inc.4.46-1.98%$454.22Mvs BLSM
RZLTRezolute Inc.3.92-6.67%$465.58Mvs BLSM
MNPRMonopar Therapeutics Inc.69.00-1.84%$467.60Mvs BLSM
EVOEvotec SE ADR1.32-8.97%$469.11Mvs BLSM
KMDAKamada Ltd.7.74-1.15%$446.85Mvs BLSM

Indexes, lists and sector

BlossomHill Therapeutics stock FAQ

What is BlossomHill Therapeutics's stock price today?

BLSM last traded at $14.51 as of Nov 20, 4:00 PM EST, up 0.69% on the day. Prices are delayed at least 15 minutes.

Who is BlossomHill Therapeutics's CEO?

Dr. Jingrong Jean Cui Ph.D. is the chief executive officer of BlossomHill Therapeutics Inc., which has about 69 employees.

What is the BLSM 52-week high?

The 52-week high for BLSM is $27.99 and the 52-week low is $11.02. The stock is currently 48.2% below its high.

Compare BLSM